XML 27 R17.htm IDEA: XBRL DOCUMENT v3.26.1
WARRANTS
 3 Months Ended
Mar. 31, 2026
Warrants  
WARRANTS

7. WARRANTS

 

As of March 31, 2026, the following warrants to purchase shares of common stock were outstanding:

           
   Warrants Outstanding  

Exercise Price

per Share

   Expiry Date
June 2025 Private Placement Warrants   666,497   $7.00  

Warrant Expiry Date

(defined below)

Underwriter warrants issued under IPO   161,000   $10.00   August 12, 2027
Warrants originally issued in conjunction with Series B Redeemable Convertible Preferred Stock   76,376   $10.55   August 13, 2026
Warrants originally issued in conjunction with Series C Redeemable Convertible Preferred Stock   18,223   $9.42   August 13, 2026
Total   922,096         

 

June 2025 Private Placement Warrant

 

On June 25, 2025, the Company entered into a securities purchase agreement for a private placement of common stock and warrants with certain institutional and accredited investors, including Bios 2024 Co-Invest, LP. Dr. Aaron G.L. Fletcher, the Chairman of the Company’s Board of Directors, is a Managing Partner and co-founder of Bios Partners, of which Bios 2024 Co-Invest, LP is an affiliate entity. Upon closing of the private placement on June 27, 2025, the Company issued warrants to purchase up to an aggregate of 666,497 shares of common stock at an exercise price of $7.00 per share. The warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (“FDA”) issuing Breakthrough Therapy Designation (“BTD”) for elraglusib and (ii) the date that the FDA provides written communication available to the Company of its determination as to whether the Company may pursue registration for elraglusib using its currently available Phase 2 data or data from a future Phase 3 clinical study (“Warrant Expiry Date”).